Presentation is loading. Please wait.

Presentation is loading. Please wait.

bDMARD: biologic DMARD.

Published byMyrtle Fields Modified over 5 years ago

Similar presentations

Presentation on theme: "bDMARD: biologic DMARD."— Presentation transcript:

1 bDMARD: biologic DMARD.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Rheumatology (Oxford), Volume 58, Issue 4, 07 December 2018, Pages 683–691, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Fig. 2 Sensitivity analyses for the risk of cancer associated with abatacept as the initial bDMARD compared with ... bDMARD: biologic DMARD; HR: hazard ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Rheumatology (Oxford), Volume 58, Issue 4, 07 December 2018, Pages 683–691, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Fig. 3 Sensitivity analysis for the risk of cancer associated with the combination of bDMARD and MTX compared with ... bDMARD: biologic DMARD; CI: confidence interval; HR: hazard ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Rheumatology (Oxford), Volume 58, Issue 4, 07 December 2018, Pages 683–691, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "bDMARD: biologic DMARD."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.
Different weights (size of the circles) and ...

Different weights (size of the circles) and ...
(A) Pelvic X-ray showing diffuse osteoaddensing ...

(A) Pelvic X-ray showing diffuse osteoaddensing ...

Similar presentations

Ads by Google